1. Home
  2. XFOR

XFOR

X4 Pharmaceuticals Inc.

Logo X4 Pharmaceuticals Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-16-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Founded: 2014 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 209.9M IPO Year: N/A
Target Price: $3.00 AVG Volume (30 days): 2.3M
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.57 EPS Growth: N/A
52 Week Low/High: $0.57 - $2.58 Next Earning Date: 05-02-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 316.78%

Share on Social Networks: